|
nasopharyngeal carcinoma |
43 |
|
chemoradiotherapy |
23 |
|
prognostic factors |
18 |
|
capecitabine |
15 |
|
intensity-modulated radiation therapy |
15 |
|
nomogram |
14 |
|
radiotherapy |
14 |
|
randomized controlled trial |
14 |
|
survival prediction |
14 |
|
hong kong |
12 |
|
accelerated fractionation |
10 |
|
efficacy |
10 |
|
plasma ebv dna |
10 |
|
prognostication |
10 |
|
targeted therapy |
10 |
|
late toxicity |
9 |
|
non-small cell lung cancer |
9 |
|
oncology |
9 |
|
recursive partitioning analysis |
9 |
|
stage classification |
9 |
|
toxicities |
9 |
|
chemotherapy |
8 |
|
chinese |
8 |
|
colorectal cancer |
8 |
|
hypothyroidism |
8 |
|
induction chemotherapy |
8 |
|
metastatic colorectal cancer |
8 |
|
neoadjuvant therapy |
8 |
|
non-metastatic |
8 |
|
oesophageal cancer |
8 |
|
oesophageal squamous cell carcinoma |
8 |
|
oesophagectomy |
8 |
|
survival |
8 |
|
cancer |
7 |
|
cost-effectiveness analysis |
7 |
|
epidermal growth factor receptor |
7 |
|
medical sciences |
7 |
|
nasopharyngeal cancer |
7 |
|
non-small-cell lung cancer |
7 |
|
palliative care |
7 |
|
tyrosine kinase inhibitors |
7 |
|
vaccination |
7 |
|
decision-making |
6 |
|
dosimetric predictors |
6 |
|
economic evaluation |
6 |
|
economic evidence |
6 |
|
follow up |
6 |
|
half-life clearance |
6 |
|
health care |
6 |
|
local clinical remission |
6 |
|
plasma epstein–barr virus deoxyribonucleic acid |
6 |
|
post-treatment plasma ebv dna |
6 |
|
prognosis |
6 |
|
quality of life |
6 |
|
screening |
6 |
|
simulation models |
6 |
|
survivorship |
6 |
|
systematic review |
6 |
|
thyroid cancer |
6 |
|
5-fluorouracil |
5 |
|
breast neoplasms |
5 |
|
cancer outcomes |
5 |
|
cancer site-standardized relative survival |
5 |
|
cervical cancer |
5 |
|
cetuximab |
5 |
|
cheung chau island |
5 |
|
global health |
5 |
|
health economics |
5 |
|
human papillomavirus |
5 |
|
incidence |
5 |
|
local recurrence |
5 |
|
mortality |
5 |
|
network meta-analysis |
5 |
|
pooled analysis |
5 |
|
reirradiation |
5 |
|
re‐irradiation |
5 |
|
salvage |
5 |
|
surgery |
5 |
|
survival outcome |
5 |
|
acceptance |
4 |
|
adult |
4 |
|
aged |
4 |
|
aged, 80 and over |
4 |
|
ajcc/uicc staging system |
4 |
|
anxiety |
4 |
|
assessment |
4 |
|
breast - anatomy & histology |
4 |
|
breast cancer |
4 |
|
breast neoplasms - pathology - radiography - radiotherapy - surgery |
4 |
|
cervical cancer screening |
4 |
|
chi-square distribution |
4 |
|
concurrent chemotherapy |
4 |
|
conservation |
4 |
|
covid-19 |
4 |
|
cytology and histology |
4 |
|
female |
4 |
|
hpv vaccination |
4 |
|
humans |
4 |
|
immune checkpoint inhibitors |
4 |
|
immune-related endocrine dysfunction |
4 |
|
intensity‐modulated radiotherapy |
4 |
|
liver metastases |
4 |
|
malignancy |
4 |
|
mammography - psychology - utilization |
4 |
|
manual contouring |
4 |
|
mastectomy, segmental - trends |
4 |
|
middle aged |
4 |
|
multidisciplinary |
4 |
|
neoplasm staging |
4 |
|
oncology medical sciences |
4 |
|
organ size |
4 |
|
population-based screening program |
4 |
|
prediction |
4 |
|
radiation boost |
4 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
4 |
|
recist |
4 |
|
refractory |
4 |
|
regorafenib |
4 |
|
retrospective studies |
4 |
|
spinal metastases |
4 |
|
tmn classification |
4 |
|
tnm staging |
4 |
|
tnm staging system |
4 |
|
treatment |
4 |
|
trifluridine/tipiracil (tas-102) |
4 |
|
volumetric evaluation |
4 |
|
young adult |
4 |
|
age factors |
3 |
|
asian continental ancestry group |
3 |
|
atezolizumab plus bevacizumab |
3 |
|
attitudes |
3 |
|
breast neoplasms - mortality - surgery |
3 |
|
chinese herbal medicine |
3 |
|
cost-benefit analysis |
3 |
|
cost-effective analysis |
3 |
|
disease-free survival |
3 |
|
dose constraint |
3 |
|
ercc1 |
3 |
|
familial |
3 |
|
familial risk |
3 |
|
follow-up studies |
3 |
|
graves' ophthalmopathy |
3 |
|
health expenditures |
3 |
|
hepatocellular carcinoma |
3 |
|
hepatotoxicity |
3 |
|
hpv vaccines |
3 |
|
imrt |
3 |
|
intensity-modulated radiotherapy |
3 |
|
liver toxicity |
3 |
|
markov chain model |
3 |
|
mastectomy |
3 |
|
mastectomy, modified radical |
3 |
|
mastectomy, segmental |
3 |
|
mathematical model |
3 |
|
neoplasm recurrence, local |
3 |
|
parapharyngeal space |
3 |
|
patient outcome assessment |
3 |
|
pattern of failure |
3 |
|
predictive |
3 |
|
retro-orbital irradiation |
3 |
|
rucam |
3 |
|
sensorineural hearing loss |
3 |
|
sexual mixing |
3 |
|
staging system |
3 |
|
survival rate |
3 |
|
tnm |
3 |
|
traditional chinese medicine |
3 |
|
tumor control probability |
3 |
|
abiraterone (aa) |
2 |
|
apalutamide |
2 |
|
bivalent vaccine |
2 |
|
central line |
2 |
|
central venous access devices |
2 |
|
cervix uteri - cancer - prevention |
2 |
|
complications |
2 |
|
cost-effectiveness |
2 |
|
docetaxel |
2 |
|
end-of-life care |
2 |
|
enzalutamide (enz) |
2 |
|
hcc |
2 |
|
meta-analysis |
2 |
|
nonavalent vaccine |
2 |
|
palbi |
2 |
|
papillomavirus vaccines |
2 |
|
peripherally inserted central catheter |
2 |
|
prostate cancer |
2 |
|
signs and symptoms |
2 |
|
socioeconomic factors |
2 |
|
time factors |
2 |
|
totally implanted port |
2 |
|
transmission dynamic model |
2 |
